The Week in Review: July 27 – August 24, 2018

Friday, August 24, 2018 News Recap: Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...

New online calculator predicts clinical improvement in liver failure after Hep C treatment

Investigators formulated a five-factor metric known as the BE3A score that offers specialists a shared decision-making tool to predict potential improvements after treatment in patients with hepatitis C virus (HCV)-associated liver failure, as detailed in a new study published in Gastroenterology. The five factors in the BE3A score include body mass index (BMI), encephalopathy, ascites, and serum levels of both alanine aminotransferase (ALT) and albumin.

The Week in Review: January 19 – January 26, 2018

Friday, January 26, 2018 News Recap: Research and Discoveries: Growing Evidence Shows Hepatitis C Intersects With Other Diseases. As many as three-quarters of individuals with hepatitis C virus (HCV) experience disorders related to the virus beyond the impact on their livers, the National Viral Hepatitis Roundtable estimates. HCV-related kidney disease, depression, skin disorders, lymphoma and other conditions can seriously impact a patient, even wi...

Ribavirin Remains Pivotal Component of Hepatitis C Treatment

We’re living in an era where there are highly effective direct-acting antivirals (DAA) available for the treatment of chronic hepatitis C virus, but ribavirin (RBV) continues to be a necessary adjunct to DAA regimens for the virus. A new cohort study published online in Alimentary Pharmacology and Therapeutics in November confirmed the RBV steady-state serum levels that correspond to high rates of efficacy and low adverse effect. Co-lead authors of the

Health Canada Approves DAKLINZA™ (daclatasvir) for Difficult-to-Treat Hepatitis C Patient Populations

DAKLINZA™ is approved in Canada in combination with other agents for the treatment of chronic hepatitis C Patients with HIV co-infection, advanced cirrhosis and post-liver transplant HCV recurrence MONTREAL, May 24, 2016 /CNW/ - Bristol-Myers Squibb Canada today announced Health Canada's approval of DAKLINZA™ (daclatasvir), in combination with sofosbuvir (with or without ribavirin) for 12 weeks in the treatment of chronic hepatitis C (CHC) in adult patie

U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease

– Liver Transplant Patients and Those with Decompensated Cirrhosis Can Now be Treated With 12 Weeks of All-Oral Therapy –FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 16, 2016-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved additional indications for Harvoni® (ledipasvir/sofosbuvir) for use in chronic hepatitis C patients with advanced liver disease. Harvoni in combination with ribavirin (RB

Combination therapy successfully treats hepatitis C in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine (NEJM). "More than half of the patients in the study

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie

Oct 22, 2015The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak [Holkira Pak in Canada] and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.Patients taking these medicines should contact their health care professional immediately if they develop fatigue